Stock Analysis
Zymeworks Inc. (ZYME) Stock Analysis
Zymeworks Inc. (ZYME) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Zymeworks Inc. (ZYME) currently has an AIQ Score of 68/100, indicating a bullish setup. Momentum is the strongest factor at 78/100. Risk is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ZYME at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $26.24 |
| AIQ Score | 68/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Sell |
| Market Cap | $1.88B |
| P/E Ratio (TTM) | 39.16 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $2.43 |
| Revenue (Q3 FY2026) | $256.46M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.78 |
| Volume | 774.98K |
| 52-week range | $18.20-$31.97 |
| RSI 14 | 41.96 |
| 50-Day SMA | $27.32 |
| 200-Day SMA | $25.52 |
| Analyst Price Target | $42.60 |
| Next Earnings | Mar 1, 2027 |
ZYMEZymeworks Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum78
- Value66
- Quality62
- Risk resilience61
- Sentiment—
ZYME Stock Analysis Summary
Zymeworks Inc. (ZYME) currently has an AIQ Score of 68/100, indicating a bullish setup. Momentum is the strongest factor at 78/100. Risk resilience is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, ZYME has AIQ Score of 68/100 with Momentum base of 78/100 and fading Risk resilience at 61/100. Wait for component alignment before adding exposure.
Healthcare · -0.87% stock move · ZYME classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ZYME Bullish or Bearish Right Now?
ZYME currently has a bullish overall setup. Momentum is the strongest factor at 78/100, while Risk Resilience is weakest at 61/100. The current evidence suggests a constructive setup.
- - Momentum is constructive at 78/100.
- - Analyst target implies +62.35% upside from the latest quote.
- - Technical consensus has more sell votes than buy votes (29 vs 14).
Current Consensus
ZYME's Technical Analysis Consensus is currently Sell, with 14 buy, 3 neutral, and 29 sell votes. ZYME's 14-day RSI is 41.96, which places the stock in a weaker momentum range. ZYME's beta is 0.78, indicating lower market sensitivity than the broad market.
What Changed in ZYME?
The largest recent change in ZYME is Value moving up by 24.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ZYME Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ZYME Decision Framework
Public evidence layers, setup checks, and risk context for Zymeworks Inc..
Zymeworks Inc. (ZYME) Stock Analysis
Zymeworks Inc. has an AIQ Score of 68/100 in a Bullish regime. Momentum is strongest at 78/100. Beta is 0.78, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ZYME is in a Bullish AIQ regime with score 68/100. |
| Signal Conflict | The primary conflict is that momentum leads at 78/100 while risk lags at 61/100. |
| Factor Evidence | Momentum 78/100 · Value 66/100 · Quality 62/100 · Risk 61/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 78/100.
Momentum is 78/100 and RSI (14) is 42.0.
ZYME is in a Bullish regime at 68/100.
Risk factor is 61/100 with beta 0.78 and annual volatility 54.03%.
Current conflict: momentum leads at 78/100 while risk lags at 61/100.
ZYME Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ZYME Fundamentals
ZYME valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ZYME Technical Analysis
ZYME technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ZYME Stock Catalysts
Track ZYME earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ZYME Dividend Analysis
ZYME dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ZYME Financial Data
ZYME revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ZYME Risk Analysis
ZYME volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ZYME Stock News
ZYME stock news, market tone, recent headlines, and catalyst context.
ZYME vs Biotechnology Peers
Current peer cohort: ZYME · ABCL · ABSI · ABUS · ABVX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ZYME Current stock | 68/100 | 66/100 | 78/100 | 61/100 | 0.84 | 54.03% | Current |
| ABCL AbCellera Biologics Inc. | 64/100 | 47/100 | 89/100 | 34/100 | 1.73 | 85.28% | ZYME vs ABCL |
| ABSI Absci Corporation | 53/100 | — | 85/100 | 30/100 | 1.58 | 104.15% | ZYME vs ABSI |
| ABUS Arbutus Biopharma Corp | 70/100 | 92/100 | 51/100 | 62/100 | -0.09 | 45.89% | ZYME vs ABUS |
| ABVX Abivax S.A. | 35/100 | — | 34/100 | 37/100 | 0.24 | 86.44% | ZYME vs ABVX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ZYME: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ZYME
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ZYME
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ZYME Stock FAQ
What is ZYME stock price today?
Zymeworks Inc.'s current stock price is $26.24. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ZYME bullish or bearish right now?
ZYME's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ZYME's market cap?
ZYME's market cap is $1.88B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ZYME's current P/E ratio?
ZYME's current P/E ratio is 39.16 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ZYME's RSI?
ZYME's 14-day RSI is 41.96 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ZYME above its 50-day and 200-day moving averages?
ZYME is -3.95% from its 50-day SMA and 2.81% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ZYME's next earnings date?
ZYME's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ZYME pay a dividend?
ZYME's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.